A new, powerful Citizen Portal experience is ready. Switch now

FDA‑funded tobacco inspection unit fully staffed; Q1 shows 87% compliance rate

May 13, 2026 | Board Council Commission Agencies , Executive, Washington


This article was created by AI summarizing key points discussed. AI makes mistakes, so for full details and context, please refer to the video of the full meeting. Please report any errors so we can fix them. Report an error »

FDA‑funded tobacco inspection unit fully staffed; Q1 shows 87% compliance rate
Susan Ekstrom, the LCB's FDA program coordinator, told the May 13 meeting that the division operates a five‑year contract with the U.S. Food and Drug Administration that funds six full‑time tobacco inspectors and a program coordinator. "We conduct tobacco inspections across all Washington state tobacco and vapor product retailers," she said, describing two primary inspection types: undercover buy attempts to detect underage sales and advertising/labeling inspections to verify warnings and authorized displays.

Ekstrom said the team's goal is an annual inspection of every retailer; if a retailer is in compliance during a check, the contract prohibits further FDA inspections that year, but out‑of‑compliance findings trigger FDA follow‑up and potential multiple checks. She described the FDA adjudication flow: inspectors submit reports to the FDA; if the FDA agrees a violation occurred it issues a notice and may ultimately impose penalties—first a warning, then civil monetary penalties or a no‑tobacco‑sales order for repeat offenders.

Judy Edwards and Susan provided quarter‑one statistics for the FDA program: 876 inspections in the quarter, including 205 advertising and labeling reviews and 671 undercover buy attempts; 90 referrals were made for underage sales, yielding an 87% compliance rate for the quarter. The presenters cautioned that FDA public reporting lags until the agency completes its adjudication, and said the LCB research team is building dashboards to publish finalized data once actions are adjudicated.

A board member asked how Washington's program compares to other states. Ekstrom and Chief Grant said state programs differ—contracts and reporting structures vary—so straightforward state‑to‑state comparisons are often imperfect. The presenters said Washington historically checks a high share of locations and was among the earlier adopters of the FDA cooperative contract model.

Don't Miss a Word: See the Full Meeting!

Go beyond summaries. Unlock every video, transcript, and key insight with a Founder Membership.

Get instant access to full meeting videos
Search and clip any phrase from complete transcripts
Receive AI-powered summaries & custom alerts
Enjoy lifetime, unrestricted access to government data
Access Full Meeting

30-day money-back guarantee